Vir Biotechnology Quarterly Cash Flow Statement
NASDAQ: VIRHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Vir Biotechnology free cash flow
In the quarter ended Jun 30, 2026, Vir Biotechnology generated $123.3 million of operating cash flow and spent $32,000 on capital expenditures. That left free cash flow of $123.3 million, a free-cash-flow margin of 51.6% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Vir Biotechnology cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 80.08M | -125.69M | -42.92M | -163.14M | -110.96M | -120.97M | -104.59M | -213.72M | -138.38M | -65.28M | -115.97M | -163.41M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | -193.21% |
| Depreciation & Amortization | 2.80M | 2.81M | 2.90M | 3.00M | 2.92M | 2.87M | 2.89M | 2.90M | 4.26M | 4.52M | 4.48M | 4.50M |
| Stock-Based Compensation | 12.39M | 12.09M | 11.21M | 11.36M | 12.45M | 14.06M | 15.84M | 16.70M | 22.16M | 23.76M | 28.27M | 26.94M |
| Change in Working Capital | 11.71M | -3.57M | -5.76M | -8.87M | -300.00K | 4.07M | -13.73M | 3.28M | -518.00K | -49.91M | -808.00K | -5.76M |
| Operating Cash Flow | 123.33M | -132.39M | -25.88M | -167.57M | -120.22M | -78.12M | -87.64M | -171.48M | -77.85M | -109.39M | -107.93M | -155.83M |
| Capital Expenditures | -32.00K | -390.00K | -348.00K | -317.00K | -2.54M | -1.63M | -2.00M | -2.77M | -666.00K | -1.87M | -1.53M | -3.71M |
| Investing Cash Flow | -197.14M | 11.84M | 86.65M | 40.45M | 56.46M | 126.82M | 140.74M | 118.60M | 211.61M | 28.42M | -104.81M | -58.95M |
| Financing Cash Flow | 78.38M | 162.52M | 1.04M | 102.00K | 2.05M | 598.00K | 1.26M | 31.00K | 2.94M | 152.00K | 1.68M | 277.00K |
| Net Change in Cash | 4.56M | 41.97M | 61.81M | -127.02M | -61.72M | 49.30M | 54.37M | -52.85M | 136.70M | -80.82M | -211.06M | -214.51M |
| Free Cash Flow | 123.29M | -132.78M | -26.22M | -167.89M | -122.76M | -79.75M | -89.63M | -174.25M | -78.51M | -111.26M | -109.46M | -159.54M |
This table shows 12 quarterly periods of Vir Biotechnology's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow VIR's reporting calendar. What is a cash flow statement?